The potential efficacy of screening for trisomy 21 in the first trimester, using maternal serum markers 01 fetoprotein, free fJ human chorionic gonadotropin, unconjugated oestriol and pregnancy associated plasma protein A, was studied in an unselected population of women between the seventh and fourteenth week of gestation. Using a combination of 01 fetoprotein and free fJ human chorionic
gonadotropin, 53070 of affected pregnancies could be identified at a false positive rate of 5%. Unconjugated oestriol and pregnancy associated plasma protein A levels were lower in cases of trisomy 21, but their inclusion with other markers did not significantly improve detection rate. Monitoring the same pregnancies also in the second trimester showed that screening in the first trimester identified the same cases as in the second. We conclude that first trimester screening using free fJ human chorionic gonadotropin and 01 fetoprotein, is a viable possibility and will lead to detection rates in excess of 50%. Prospective studies are needed to confirm these observations.
Additional key phrases: Down's syndrome; unconjugated oestriol; trisomy 18
Prenatal screening for trisomy 21 using biochemical markers in maternal serum during the second trimester is now routinely carried out in many centres. Of the markers investigated a combination of 01 fetoprotein (AFP) and free fJ human chorionic gonadotropin (fJ-hCG) has been shown both retrospectively'r! and prospectively'v? to achieve detection rates of 65-75% in routine screening.
The disadvantage of screening for genetic anomalies in the second trimester is the likelihood of late termination of an affected pregnancy. Advancing biochemical screening into the first trimester would therefore offer considerable benefits particularly in those centres that have access to chorionic villus sampling (CYS) or early amniocentesis.
Candidate markers for trisomy 21 in the first trimester include AFP, 10-12 unconjugated Correspondence: Dr K Spencer oestriol't-!" and free fJ-hCG . 15, 16 Total or intact hCG, found valuable in the second trimester 17 -19 has been shown to be ineffective in the first. 12.13,20-23 Brambati et al. 24 and Wald et al. 25 have suggested that pregnancy associated plasma protein A (P APP-A) may be a useful marker in the first trimester. In this study we have assessed the potential of P APP-A, in combination with other analytes in screening for trisomy 21 in the first trimester.
STUDY POPULATIONS
Samples were collected from two centres: west of Scotland and Oldchurch. In the west of Scotland centre maternal serum samples were collected at 6-14 weeks gestation from 14 ()()() consecutive women who attended antenatal clinics between January 1987 and April 1990. 23 From this set, serum samples from 16 trisomy 21 pregnancies were available for study. Three of these had been prenatally diagnosed at 8-13 weeks gestation following CVS indicated for maternal age. Of the remaining 13 cases, one was diagnosed at 20 weeks gestation and 12 continued to term with delivery of an affected infant. Gestational age at the time of sampling was estimated from the ultrasound scan or, in its absence from the date of last menstrual period. In addition, five cases of trisomy 18 were also available for study: four of these were prenatally diagnosed by CVS and one by second trimester screening. The AFP, UE3 and free {1-hCG data for these trisomy 21 and trisomy 18 cases have been previously reported. 1S, 16, 23 From the 14000 pregnancies, 320 samples from unaffected pregnancies were selected at random to serve as controls. These comprised 40 samples at each completed week of gestation (7-14 weeks).
In the Oldchurch centre serum samples from five cases of trisomy 21 were available. These samples were collected during 1986 to 1989 and thought to be have been collected in the second trimester, but on ultrasound examination the gestational age was found to be in the first trimester. These samples were collected as part of routine population screening for neural tube defects and had been stored at -20°C. Two of the five cases were terminated in the second trimester after amniocentesis on account of maternal age, the remaining three resulted in delivery of an affected infant. Of the five cases, three had further samples taken at 16-18 weeks after ultrasound revision of gestational dates. Table 1 summarizes maternal ages and gestational ages of the subjects studied in the first trimester.
To derive reference data for PAPP-A during second trimester, samples from five unaffected pregnancies matched for gestational age, maternal age and length of storage were analysed for each of the 12 trisomy 21 cases.
BIOCHEMICAL METHODS
The biochemical markers AFP, UE3, free {1-hCG and PAPP-A were assayed on all samples. First trimester AFP levels were measured using an inhouse immunoradiometric assay26 with a detection limit better than 1 KU/L and a between assay coefficient of variation (CV) of 9· 5% at 10 KU/L. Unconjugated oestriol was measured using a modified form of the Kodak Diagnostic Amerlex M (second trimester) assay. To improve the sensitivity the sample volume was increased fivefold and additional calibrators were prepared by dilution with pooled male serum. The detection limit of the assay was O' 18 nmol/L and a between assay CV was 9· 8OJo at 2 nmol/L. Free {1-hCG was measured in the first trimester samples by a microtitre plate ELISA method-? with a dectection limit of 1 lUlL and a between assay CV of 3·2% at 62 lUlL. P APP-A was measured using an ELISA method. The polyclonal capture antibody to PAPP-A (Catalog No. A230, Dako A/S, Glostrup, Denmark) was coated onto the surface of microtitre plates. The assay was calibrated using a diluted third trimester pregnancy pool standardized against PAPP-A in the World Health Organization 78/610 reference preparation for pregnancy associated proteins.
All incubations were performed on a rotator (200 rpm). Thirty-five microlitres of standards, controls (at three levels of pooled pregnancy sera) or samples, in duplicate, were incubated with 70 ILL of assay buffer (0' 05 M phosphate buffered saline including stabilizer) in the coated microtitre well for 120 min. After washing 28 100 ILL of biotinylated polyclonal antibody to P APPA-A (Dako) was incubated for 15 min. After another wash the plate was incubated with 100 ILL of streptavidin-horseradish peroxidase conjugate for 6 min. After a final wash plates were incubated with 100 ILL of 3, 3' , 5, 5' tetramethylbenzidine (TMB)/Peroxidase substrate solution for 6 min after which the reaction was stopped with 100ILL Control and samples values were computed from a four parameter curve fitting routine. Samples greater than the top calibrator (16 KU/L) were appropriately diluted in assay buffer and reassayed. The detection limit of this assay was found to be 0·22 KU/L and the between assay CV was 10·54% at 2·3 KU/L. Measurement of AFP and free ,s-hCG in the sera from second trimester was performed by simultaneous dual analyte microtitre plate ELISA method.V" STATISTICAL ANALYSIS To take into account variation of marker levels with gestational age, all results were expressed as multiples of the median (MoM) of the appropriate gestational control group after logarithmic transformation. Median values for AFP, itee B.
hCG and UE3 have been previously published.P Statistical analysis of the data was performed using Unistat Statistical Software Package (Unistat Ltd, London, UK) with the statistical tests identified in the text. Calculation of the risk of Down's syndrome using combinations of biochemical parameters, and the maternal age risk,29 was performed according to the procedure outlined by Reynolds and Penney" using population constants derived from this present study. In addition likelihood ratios generated from various combinations of biochemical markers were entered into a statistical population model to stimulate the effect of screening a typical UK population model in the first trimester. The distribution of risk in trisomy 21 and unaffected pregnancies was found by numerically integrating the distribution of age and the multivariate Gaussian density function over a grid of values of age and the corresponding values as described by Wald et 0/. 18 The distribution of ages in trisomy 21 and unaffected pregnancies was derived by applying the age specific risk of a trisomy 21 term pregnancy" to the number of pregnant women of different ages in England and Wales in 1986-1989 (Office of Population Census and Statistics).
RESULTS
PAPP-A levels during the first trimester increased logarithmically with gestational age (Fig. 1) . Figure 2 shows the concentration of P APP-A in cases of trisomy 21 and trisomy 18 during the Down's syndrome screening 449 were significantly lower than in unaffected pregnancies (P<O·01, and P<O'01, respectively). Table 2 summarizes the distribution of the four analytes in the unaffected and trisomy 21 pregnancies. The probability density function of logto PAPP-A MoM showed incomplete normalization of distribution as shown by the Kolmogorov-Smirnov test ( Table 3 ). In order to use only the linearly related data, boundary limits of O' 3 MoM and 3· 0 MoM were applied and used in calculation of likelihood ratios, such that all values below O' 3 MoM were treated as O' 30 MoM and all values above 3· 0 MoM were treated as 3·OMoM.
Free ,9-hCG approached a normal distribution on log transformation (Table 3 ) and boundary limits of O' 1 to 5·0 were used. For UE3 and aFP logto transformation normalized the distribution (Table 3) .
Detection rates
Receiver operator characteristic (ROC) curves for the four analytes ( Fig. 3) shows that free ,9-hCG had the greatest predictive value for trisomy 21. At a 5% false positive rate, free {j-hCG identified, 430/0 of the cases. Table 4 shows the detection rate of various combinations of analytes at a 5% false positive rate. Detection rates of 53% (CI 30-75) could be achieved by a combination of free {j-hCG and AFP. Adding a third analyte to this combination did not appear to increase the detection rate further.
Longitudinal studies between first and second trimester Table 5 shows the MoM values for AFP, free {j-hCG and PAPP-A in the 12 cases of trisomy 21 at first and second trimesters. Although AFP values showed considerable individual variation the median of MoM remained unchanged between the two trimesters. Median for free {j-hCG in the second trimester was fractionally lower than that in the second trimester. The median PAPP-A value for trisomy 21 cases in the second trimester (1' 08 MoM) was not significantly different from that of the control group. Figure 4 shows the individual risk for trisomy 21 in the first and second trimester calculated using AFP and free {j-hCG and maternal age. If a risk cut off of a 5% false positive rate is used (one in 200 at term for first trimester, one in 275 at term for second trimester), then seven of 12 cases which reached term would have been detected in the first trimester and six of these seven cases would have also been detected in the second trimester ( Fig. 4) . 
DISCUSSION
In nearly all previous studies of first trimester screening samples obtained from patients prior to CVS for advanced maternal age have been used. Such studies are not truly representative.
As there was no biases in patient selection, our sample is truly representative of a first trimester population.
The study confirms that maternal serum PAPP-A in the first trimester is significantly lower in cases of trisomy 21 and trisomy 18. 24 ,25 The median PAPP-A values in trisomy 21, however, is higher than that reported in two other studies 24 ,25 which Down's syndrome screening 451 used pre-CVS samples. It is unclear whether any of the samples in these two studies were identical. In a study where cases that had survived into the fifteenth week of pregnancy'! were used the median value was higher than in the initial studies. 24 ,25 The very low PAPP-A in the earlier studies may be indicative of potential fetal loss. The second trimester median PAPP-A values are not significantly different from the control group. Using a combination of AFP and free {j-hCG in the first trimester we have demonstrated that, 53070 of those trisomy 21 pregnancies that reached term could be detected. We have also demonstrated, albeit in a limited number of cases, that these cases are likely to be the same as those detected in the second trimester using the same marker combination. This detection rate in the first trimester is similar to the reported detection rates of 50-55% using the triple markers (AFP, UE3, total hCG) in second trimester and 10-15% lower than that achieved using AFP and free {j-hCG. [34] [35] 100000 -:::r----------------., Addition of P APP-A and/or UE3 to AFP and free l3-hCG combination did not improve the detection rate. Furthermore analysis of PAPP-A on a routine basis is difficult since there are no commercially available assays. Assay specificity is unlikely to account for the differences in our study compared with those of others 2S ,33,36 as the same polyclonal antibody was used in all studies. Indeed our median data for unaffected pregnancies are very similar to those derived from the formula quoted by Macintosh and Chard." The wide spread of results in both the affected and unaffected pregnancies and the fact that the reduced levels in the first trimester become normal in the second trimester further restrict the potential use of PAPP-A to a narrow gestational age range. The combination of AFP and free l3-hCG, on the other hand, can be used across a wide gestational window (7-20 weeks) and re-dating of gestation will not require analysis of new markers.
Measurement of UE3 in the first trimester requires modification of current second trimester assays as they are not sensitive enough and the validity of such assay modifications have been questioned."
Although analyte medians in this study were based upon only 40 samples at each gestational week, larger population studies have shown no significant differences between the observed medians and those used in this study (Spencer et a/., unpublished observations).
We conclude that first trimester screening for trisomy 21 using a combination of AFP free l3-hCG is a viable possibility. The introduction of such screening clearly requires careful consideration of logistics, organization, and consequences of such a programme. Women would need to attend antenatal clinics much earlier than the current practice. Alternatively screening could take place in the primary care situation, with the use of filter paper blood spots;" Other potential problems include gestational dating errors which may be even more significant than in the second trimester. Furthermore, inability to identify neural tube defects at first trimester-" may result in a twostage screening programme and/or an exclusive dependence on ultrasound to detect neural tube defects, although this has been questioned.P:"
Biochemical screening in the first trimester coupled with the increasing availability of early amniocentesis.vP the use of new techniques such as amnifiltration" and fluorescence in situ hybridization for chromosomal identification." make it possible for the diagnosis and termination of trisomy 21 before the thirteenth week of pregnancy.
